I think it might not be the most helpful distinction. My own assessment is that CEPA as it stands now is more of a risk-based regime, and that we should be moving closer to a hazard-based regime. I don't think there's a stark bright line there that we need to pay attention to. I think we can work towards amendments to provisions in CEPA that will move us closer to a hazard-based regime. It falls short, for example, with respect to low doses that are implicated in endocrine disruption. We want to pay attention to the hazard of endocrine disruptors because we know that very low doses are critical. This more risk-based approach says that there's a threshold below which health effects won't occur and that people can make choices as consumers on whether or not they accept the risk. This is not the right way to go.
On June 9th, 2016. See this statement in context.